tetano
Editor, Senior Moderator
Vaccine
. 2021 Nov 8;S0264-410X(21)01435-3.
doi: 10.1016/j.vaccine.2021.11.001. Online ahead of print.
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
Kai Wu[SUP] 1 [/SUP], Angela Choi[SUP] 2 [/SUP], Matthew Koch[SUP] 2 [/SUP], Sayda Elbashir[SUP] 2 [/SUP], LingZhi Ma[SUP] 2 [/SUP], Diana Lee[SUP] 2 [/SUP], Angela Woods[SUP] 2 [/SUP], Carole Henry[SUP] 2 [/SUP], Charis Palandjian[SUP] 2 [/SUP], Anna Hill[SUP] 2 [/SUP], Hardik Jani[SUP] 2 [/SUP], Julian Quinones[SUP] 2 [/SUP], Naveen Nunna[SUP] 2 [/SUP], Sarah O'Connell[SUP] 3 [/SUP], Adrian B McDermott[SUP] 3 [/SUP], Samantha Falcone[SUP] 2 [/SUP], Elisabeth Narayanan[SUP] 2 [/SUP], Tonya Colpitts[SUP] 2 [/SUP], Hamilton Bennett[SUP] 2 [/SUP], Kizzmekia S Corbett[SUP] 3 [/SUP], Robert Seder[SUP] 3 [/SUP], Barney S Graham[SUP] 3 [/SUP], Guillaume B E Stewart-Jones[SUP] 2 [/SUP], Andrea Carfi[SUP] 2 [/SUP], Darin K Edwards[SUP] 4 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic. Safe and effective COVID-19 vaccines are now available, including mRNA-1273, which has shown 94% efficacy in prevention of symptomatic COVID-19 disease. However, the emergence of SARS-CoV-2 variants has led to concerns of viral escape from vaccine-induced immunity. Several variants have shown decreased susceptibility to neutralization by vaccine-induced immunity, most notably B.1.351 (Beta), although the overall impact on vaccine efficacy remains to be determined. Here, we present the initial evaluation in mice of 2 updated mRNA vaccines designed to target SARS-CoV-2 variants: (1) monovalent mRNA-1273.351 encodes for the spike protein found in B.1.351 and (2) mRNA-1273.211 comprising a 1:1 mix of mRNA-1273 and mRNA-1273.351. Both vaccines were evaluated as a 2-dose primary series in mice; mRNA-1273.351 was also evaluated as a booster dose in animals previously vaccinated with mRNA-1273. The results demonstrated that a primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against B.1.351, while mRNA-1273.211 was effective at providing broad cross-variant neutralization. A third (booster) dose of mRNA-1273.351 significantly increased both wild-type and B.1.351-specific neutralization titers. Both mRNA-1273.351 and mRNA-1273.211 are being evaluated in pre-clinical challenge and clinical studies.
Keywords: Booster dose; COVID-19; Neutralization; Primary series; SARS-CoV-2 variants of concern; mRNA-1273.
. 2021 Nov 8;S0264-410X(21)01435-3.
doi: 10.1016/j.vaccine.2021.11.001. Online ahead of print.
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
Kai Wu[SUP] 1 [/SUP], Angela Choi[SUP] 2 [/SUP], Matthew Koch[SUP] 2 [/SUP], Sayda Elbashir[SUP] 2 [/SUP], LingZhi Ma[SUP] 2 [/SUP], Diana Lee[SUP] 2 [/SUP], Angela Woods[SUP] 2 [/SUP], Carole Henry[SUP] 2 [/SUP], Charis Palandjian[SUP] 2 [/SUP], Anna Hill[SUP] 2 [/SUP], Hardik Jani[SUP] 2 [/SUP], Julian Quinones[SUP] 2 [/SUP], Naveen Nunna[SUP] 2 [/SUP], Sarah O'Connell[SUP] 3 [/SUP], Adrian B McDermott[SUP] 3 [/SUP], Samantha Falcone[SUP] 2 [/SUP], Elisabeth Narayanan[SUP] 2 [/SUP], Tonya Colpitts[SUP] 2 [/SUP], Hamilton Bennett[SUP] 2 [/SUP], Kizzmekia S Corbett[SUP] 3 [/SUP], Robert Seder[SUP] 3 [/SUP], Barney S Graham[SUP] 3 [/SUP], Guillaume B E Stewart-Jones[SUP] 2 [/SUP], Andrea Carfi[SUP] 2 [/SUP], Darin K Edwards[SUP] 4 [/SUP]
Affiliations
- PMID: 34815117
- DOI: 10.1016/j.vaccine.2021.11.001
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic. Safe and effective COVID-19 vaccines are now available, including mRNA-1273, which has shown 94% efficacy in prevention of symptomatic COVID-19 disease. However, the emergence of SARS-CoV-2 variants has led to concerns of viral escape from vaccine-induced immunity. Several variants have shown decreased susceptibility to neutralization by vaccine-induced immunity, most notably B.1.351 (Beta), although the overall impact on vaccine efficacy remains to be determined. Here, we present the initial evaluation in mice of 2 updated mRNA vaccines designed to target SARS-CoV-2 variants: (1) monovalent mRNA-1273.351 encodes for the spike protein found in B.1.351 and (2) mRNA-1273.211 comprising a 1:1 mix of mRNA-1273 and mRNA-1273.351. Both vaccines were evaluated as a 2-dose primary series in mice; mRNA-1273.351 was also evaluated as a booster dose in animals previously vaccinated with mRNA-1273. The results demonstrated that a primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against B.1.351, while mRNA-1273.211 was effective at providing broad cross-variant neutralization. A third (booster) dose of mRNA-1273.351 significantly increased both wild-type and B.1.351-specific neutralization titers. Both mRNA-1273.351 and mRNA-1273.211 are being evaluated in pre-clinical challenge and clinical studies.
Keywords: Booster dose; COVID-19; Neutralization; Primary series; SARS-CoV-2 variants of concern; mRNA-1273.